Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja, Jose L
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. [electronic resource] - Liver international : official journal of the International Association for the Study of the Liver Jan 2015 - 90-100 p. digital
Publication Type: Clinical Trial; Journal Article; Multicenter Study
1478-3231
10.1111/liv.12656 doi
Compassionate Use Trials
Drug Therapy, Combination--adverse effects
Hepacivirus--genetics
Hepatitis C--complications
Humans
Interferon-alpha--adverse effects
Liver Cirrhosis--drug therapy
Male
Middle Aged
Polyethylene Glycols--adverse effects
Proline--adverse effects
Prospective Studies
Protease Inhibitors--adverse effects
Recombinant Proteins--adverse effects
Ribavirin--adverse effects
Spain
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. [electronic resource] - Liver international : official journal of the International Association for the Study of the Liver Jan 2015 - 90-100 p. digital
Publication Type: Clinical Trial; Journal Article; Multicenter Study
1478-3231
10.1111/liv.12656 doi
Compassionate Use Trials
Drug Therapy, Combination--adverse effects
Hepacivirus--genetics
Hepatitis C--complications
Humans
Interferon-alpha--adverse effects
Liver Cirrhosis--drug therapy
Male
Middle Aged
Polyethylene Glycols--adverse effects
Proline--adverse effects
Prospective Studies
Protease Inhibitors--adverse effects
Recombinant Proteins--adverse effects
Ribavirin--adverse effects
Spain